Supplementary Tables 1-3, Supplementary Figures 1-14 from Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma

Abstract

<p>Table S1. Demographic and clinical characteristics of the analyzed patients; Table S2. Antibodies and conditions used for the IHC studies; Table S3. List of immune-related genes analyzed by Low Density Array; Figure S1. Gating and data analysis strategy; Figure S2. CD4+ and CD8+ T-cell differentiation in ccRCC TIL, and autologous PBL and RIL; Figure S3. Gap statistics according to the possible number of clusters of TIL phenotype. Optimal cut-off according to firstSEmax method (R package: cluster) is displayed (dotted line); Figure S4. PCA analysis including RIL and TIL phenotype. TIL clusters are displayed; Figure S5. Tumor size according to TIL clusters; Figure S6. Percentages of CD4+TIL expressing AM and InR according to tumor clusters. C1, Cluster1; C2, Cluster2; C3, Cluster3; Figure S7. Percentages of CD8+TIL expressing AM and InR according to tumor clusters. C1, Cluster1; C2, Cluster2; C3, Cluster3; Figure S8. Clonality Index and frequency of top 15 clonotypes in CD8+PD-1+ TIL according to tumor clusters. C1, Cluster1; C2, Cluster2; C3, Cluster3; Figure S9. Corrected P values for the differential gene expression between TIL clusters; Figure S10. Correlation matrix including TLS-related genes and immune cells densities in Immune-activated and Immune-regulated tumors; Figure S11. Percentages of CD4+PBL expressing differentiation markers, AM and InR in healthy controls (HC) and ccRCC-bearing patients; Figure S12. Percentages of CD8+PBL expressing differentiation markers, AM and InR in HC and ccRCC-bearing patients; Figure S13. Percentages of CD4+PBL expressing differentiation markers, AM and InR according to PBL Clusters; Figure S14. Percentages of CD8+PBL expressing differentiation markers, AM and InR according to PBL Clusters.</p>